Pharma News
Looking out for latest news on Pharma Magazine?
Check out the latest Pharma news, Top news in Pharma Magazine, Leading Magazine in Pharma industry. Daily news updates pertinent to the industrial sectors we are engaged with are depicted on the news section of Pharma industry which we operate.
UniCAR Therapy and Terumo BCT Collaborate to Advance CAR T-Cell Therapies and Create a Shanghai, China Center of Excellence
Wednesday, October 10, 2018Shanghai UniCARTherapy BioMedicine Technology Co chose Terumo BCT and its cell expansion devices to automate its cell therapy manufacturing process for chimeric antigen receptor CAR Tcell therapies Privately held UniCAR will open their Center of Exce...
Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices
Tuesday, October 09, 2018Sarepta Therapeutics Inc a commercialstage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases announced today that it has entered into a longterm strategic manufacturi...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
Tuesday, October 09, 2018Novan Inc today announced that the Company has expanded its partnership with Sato Pharmaceutical Co Ltd Sato a Japanese company with a prescription pharmaceutical business specializing in dermatology to include Novans topical nitric oxidereleasing pr...
Akcea and Ionis Announce Approval of TEGSEDI ™ (Inotensive Injection) in Canada
Monday, October 08, 2018Akcea Therapeutics Inc a company affiliated with Ionis Pharmaceuticals Inc and Ionis Pharmaceuticals Inc NASDAQ IONS today announced the approval of TEGSEDI Inotersen injection in Canada for the treatment of stage or polyneuropathy in adult patie...
FDA Grants Coordination Pharmaceuticals IND Approval for CPI-100, a Novel Antitumor Nanomedicine
Saturday, October 06, 2018Coordination Pharmaceuticals Inc CPI a privately held and clinicalstage biopharmaceutical company focused on nanotechnologybased cancer immunotherapy announced today that the US Food and Drug Administration FDA has approved the Companys Investigation...
Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection
Friday, October 05, 2018The Janssen Pharmaceutical Companies of Johnson Johnson today announced that Janssen Pharmaceuticals Inc Janssen has entered into an agreement with Arrowhead Pharmaceuticals Inc Arrowhead for an exclusive worldwide license to develop and commerciali...
Acurx Pharmaceuticals to Enter Clinical Trials with First-In-Class Antibiotics to Treat Selected Gram-Positive Bacterial Infections
Friday, October 05, 2018Acurx Pharmaceuticals LLC announced today that it has entered into a scientific collaboration with the Research Service Division of WuXi AppTec WuXi to further advance the Companys pipeline of novel DNA polymeraseinhibiting antibiotic candidates Unde...
InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up
Thursday, October 04, 2018InMed Pharmaceuticals Inc a cannabinoidbased biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs is pleased to announce entering into...
Boston Pharmaceuticals Acquires Three Novel Anti-Infective Programs from Novartis
Thursday, October 04, 2018Boston Pharmaceuticals Inc Boston Pharmaceuticals today announced a licensing and equity agreement with Novartis through which Boston Pharmaceuticals will develop three novel antiinfective drug candidates that are part of the Novartis Infectious Dise...
GB Sciences' Drug Development Program Benefits from Establishment of Clear Pathway for Cannabis-Based Drug Approvals and Commercialization
Wednesday, October 03, 2018GB Sciences Inc has gained momentum in its innovative drug discovery program with the Drug Enforcement Administration DEAs decision to reschedule GW Pharmaceuticals Epidiolex from Schedule I to Schedule V of the Controlled Substances Act CSA In June...
